Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control
暂无分享,去创建一个
Chunyan Liu | Nusrat Harun | Mi-Ok Kim | Mi-Ok Kim | N. Harun | Chunyan Liu
[1] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[2] Keying Ye,et al. Evaluating water quality using power priors to incorporate historical information , 2006 .
[3] Emmanuel Lesaffre,et al. Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects , 2018, Pharmaceutical statistics.
[4] Joseph G Ibrahim,et al. Bayesian sequential meta‐analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program , 2014, Statistics in medicine.
[5] Leonhard Held,et al. Adaptive power priors with empirical Bayes for clinical trials , 2017, Pharmaceutical statistics.
[6] Bradley P Carlin,et al. Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.
[7] Nusrat Harun,et al. Bayesian selective response‐adaptive design using the historical control , 2018, Statistics in medicine.
[8] P. Thall,et al. Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.
[9] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[10] G. Yin,et al. Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization , 2012, Clinical Cancer Research.
[11] D. Berry. Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.
[12] Joseph G. Ibrahim,et al. The relationship between the power prior and hierarchical models , 2006 .
[13] N W Galwey,et al. Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion? , 2017, Statistics in medicine.
[14] Michael Branson,et al. A note on the power prior , 2009, Statistics in medicine.
[15] Michael D Hill,et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. , 2013, The New England journal of medicine.
[16] Joseph P. Broderick,et al. Methodology of the Interventional Management of Stroke III Trial , 2008, International journal of stroke : official journal of the International Stroke Society.
[17] Jing Ning,et al. Using short‐term response information to facilitate adaptive randomization for survival clinical trials , 2009, Statistics in medicine.
[18] Mi-Ok Kim,et al. Outcome‐adaptive randomization for a delayed outcome with a short‐term predictor: imputation‐based designs , 2014, Statistics in medicine.
[19] J. Ibrahim,et al. Power prior distributions for regression models , 2000 .
[20] Brian P Hobbs,et al. Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials , 2018, Statistical methods in medical research.
[21] Brian P Hobbs,et al. Adaptive adjustment of the randomization ratio using historical control data , 2013, Clinical trials.
[22] G. Liu. A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint , 2018, Pharmaceutical statistics.
[23] Anthony O'Hagan,et al. Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.
[24] Heinz Schmidli,et al. Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian‐frequentist approach , 2018, Biometrical journal. Biometrische Zeitschrift.
[25] T. J. Mitchell,et al. Bayesian Variable Selection in Linear Regression , 1988 .
[26] Feifang Hu,et al. Doubly adaptive biased coin designs with delayed responses , 2008 .
[27] Bradley P Carlin,et al. Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.
[28] R. Cuffe. The inclusion of historical control data may reduce the power of a confirmatory study , 2011, Statistics in medicine.
[29] Joseph G Ibrahim,et al. Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes , 2012, Biometrics.